Event: Esmo Breast 2023

ESMO 2023 Breast Cancer Highlights – Keynote 756, TROPION-Breast01, Keynote 52 | Onc Brothers

OncBrothers: Practice-Changing Cancer Discussions

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne

European Society for Medical Oncology (ESMO)

2023 What Changes Monday Morning? | ESMO Breast Cancer Webinar

Total Health | Oncology

Breast cancer at ESMO 2023: ADCs and MONARCH 3

ESMO 2023: Key messages for breast cancer treatment

Adjuvant treatment for high risk HR+ breast cancer | ESMO 2023 Breast Cancer Highlights

OncBrothers: Practice-Changing Cancer Discussions

Updates in metastatic triple-negative breast cancer at ESMO 2023

Charity event supports breast cancer research

HER2+ and PIK3DA-mutated breast cancer updates from ESMO Breast 2024

Adjuvant Therapy | 2023 Best of Breast Conference

Total Health | Oncology

Updated findings of T-DXd in DESTINY-Breast02 at ESMO Breast 2024

Advancements in metastatic ER+ breast cancer at ESMO Breast 2024

Highlights from ESMO Breast 2024: addressing toxicities in new cancer treatments

How to sequence ADCs in breast cancer? | ESMO 2023 Breast Cancer Highlights

OncBrothers: Practice-Changing Cancer Discussions

Highlights from ESMO 2023 in Breast Cancer – Keynote 756, TROPION-Breast01, Keynote 52

OncBrothers: Practice-Changing Cancer Discussions

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer

European Society for Medical Oncology (ESMO)

How to use endocrine therapy in premenopausal women with ER+ metastatic breast cancer

European Society for Medical Oncology (ESMO)

Metastatic TNBC at ESMO Breast 2024: IMpassion132 and MORPHEUS

New Results on Treatment of Early Breast Cancer - European Cancer Congress (ESMO) 2023